智通财经网·2026-03-17 09:36Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., has received approval for its injectable Cefazolin Sodium, which has passed the consistency evaluation for generic drugs, enhancing its market competitiveness and potential market share [1] Group 1: Product Approval - The injectable Cefazolin Sodium received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration [1] - The drug is indicated for treating infections caused by sensitive bacteria, including respiratory, urinary, skin, soft tissue, bone, joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for perioperative infection prevention [1] Group 2: Research and Development Investment - The company has invested approximately RMB 3.3241 million in the research and development of this drug's consistency evaluation [1] Group 3: Market Implications - Products that pass the consistency evaluation will receive greater support in areas such as medical insurance payments and procurement by medical institutions, which is expected to expand the market share of the injectable Cefazolin Sodium [1] - The successful evaluation also provides valuable experience for the company in conducting future consistency evaluations for other products [1]